AMG-458 (CAS: 913376-83-7) is a potent and selective c-MET inhibitor that has been developed for the treatment of cancer. It is an investigational drug that is currently undergoing clinical trials to determine its safety and efficacy.
Chemical name: AMG-458 has the chemical name of N-(2,2-dimethyl-3-(4-(methylsulfonyl)phenyl)-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-en-6-yl)-4-fluoro-3-(trifluoromethyl)benzamide.
Molecular formula: The molecular formula of AMG-458 is C25H21F4N3O4S.
Formula weight: The formula weight of AMG-458 is 553.52 g/mol.
CAS No: AMG-458 has the CAS number of 913376-83-7.
Top ten keywords from Google and Synonyms:
- c-MET inhibitor
- Cancer treatment
- Clinical trials
- Investigational drug
- Tyrosine kinase inhibitor
- HGF/MET pathway
- Side effects
- Small molecule inhibitor
Synonyms: AMG-458 can also be referred to as LY2875358, MGCD265, or Tivantinib.
Health benefits of this product: AMG-458 has been primarily developed for the treatment of cancer. As a c-MET inhibitor, it works by blocking the activation of the HGF/MET pathway, which is involved in tumor growth and metastasis. Clinical studies have shown that AMG-458 may be effective in treating several types of cancer, including lung, liver, and gastric cancers.
Potential effects: AMG-458 has the potential to significantly improve the treatment of cancer. Its high potency and selectivity make it a promising candidate for new cancer therapies. In addition, because it targets the HGF/MET pathway, which is involved in tumor growth and metastasis, it may provide a new treatment option for metastatic cancers that are resistant to other therapies.
Product mechanism: AMG-458 works by inhibiting the activity of c-MET, a receptor tyrosine kinase that plays a critical role in the HGF/MET signaling pathway. By blocking the activation of this pathway, AMG-458 prevents tumor growth and metastasis. Unlike some other c-MET inhibitors, AMG-458 is a small molecule inhibitor, which allows for oral dosing.
Safety: AMG-458 has been shown to be generally safe and well-tolerated in clinical trials. The most common side effects reported were mild to moderate and included fatigue, nausea, and vomiting. There were no reports of serious adverse events associated with AMG-458 use.
Side effects: While AMG-458 is generally considered safe, there are some potential side effects that should be monitored. These include gastrointestinal symptoms such as diarrhea, nausea, and vomiting, as well as fatigue, headache, and dizziness. Patients who experience these symptoms should speak with their healthcare provider.
Dosing information: The recommended dose of AMG-458 varies depending on the specific cancer being treated and the patient's individual characteristics. It is important to follow the dosing instructions provided by the healthcare provider and to take the medication at the same time each day to maintain consistent levels in the bloodstream.
Conclusion: AMG-458 is a promising new c-MET inhibitor being developed for the treatment of cancer. It has been shown to be highly effective in blocking the activation of the HGF/MET pathway, thereby preventing tumor growth and metastasis. While it is generally considered safe and well-tolerated, patients should be aware of potential side effects and speak with their healthcare provider if they experience any symptoms. As more data becomes available from ongoing clinical trials, we will continue to learn more about the safety and efficacy of AMG-458 as a cancer treatment.